Compounds > n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride
Page last updated: 2024-09-03

n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and Cushing's Syndrome

n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride has been researched along with Cushing's Syndrome in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bailie, MB; Bari Olivier, N; Fritz, MC; Hunt, SW; Langlois, DK; Pearson, PG; Schall, WD; Smedley, RC1

Other Studies

1 other study(ies) available for n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride and Cushing's Syndrome

ArticleYear
ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.
    BMC endocrine disorders, 2018, May-02, Volume: 18, Issue:1

    Topics: Acetyl-CoA C-Acetyltransferase; Adrenocorticotropic Hormone; Animals; Cushing Syndrome; Dog Diseases; Dogs; Female; Hydrocortisone; Male; Phenylurea Compounds; Tissue Distribution

2018